Cargando…

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020

Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising initial results of treatment by immune checkpoint inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simeunovic, Helena, Dickenmann, Martina, Nabergoj, Mitja, Baldomero, Helen, Masouridi‐Levrat, Stavroula, Nair, Gayathri, Schanz, Urs, Passweg, Jacob, Rovo, Alicia, Chalandon, Yves, Rebmann, Ekaterina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928795/ https://www.ncbi.nlm.nih.gov/pubmed/36819181 http://dx.doi.org/10.1002/jha2.629

Ejemplares similares

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better
por: Rebmann, Ekaterina, et al.
Publicado: (2022)

Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
por: Olearo, Flaminia, et al.
Publicado: (2020)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2016)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies
por: Paiano, Sandra, et al.
Publicado: (2015)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption
por: Morin, Sarah, et al.
Publicado: (2023)

Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation
por: Simonetta, Federico, et al.
Publicado: (2019)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation
por: Calderin Sollet, Zuleika, et al.
Publicado: (2023)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation
por: Pradier, Amandine, et al.
Publicado: (2020)

Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma
por: Zanella, Marie-Céline, et al.
Publicado: (2023)

Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Rhinovirus Infections among Hematopoietic Stem Cell Transplant Recipients: A Pre-Transplant Dilemma?
por: Barral, Sébastien, et al.
Publicado: (2022)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
por: Royston, Léna, et al.
Publicado: (2021)

High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation
por: Buhler, Stéphane, et al.
Publicado: (2019)

Correction: High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation
por: Buhler, Stéphane, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Royston, Léna, et al.
Publicado: (2022)

Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation
por: Glampedakis, Emmanouil, et al.
Publicado: (2021)

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2021)

Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT
por: Mohty, B, et al.
Publicado: (2011)

When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?
por: Roth, Romain Samuel, et al.
Publicado: (2022)

T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2022)

Human pegivirus-1 replication influences NK cell reconstitution after allogeneic haematopoietic stem cell transplantation
por: Pradier, Amandine, et al.
Publicado: (2023)

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Medinger, Michael, et al.
Publicado: (2023)

Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience
por: Kronig, Ilona, et al.
Publicado: (2021)

P1357: IMPAIRED CELLULAR RESPONSES AGAINST SARS-COV-2 AFTER COVID-19 INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
por: Mamez, A.-C., et al.
Publicado: (2022)

Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2021)

T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Pradier, A., et al.
Publicado: (2022)

Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years
por: Hofer, Kevin D., et al.
Publicado: (2022)

External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study
por: Fattinger, Nicolas, et al.
Publicado: (2022)

Phosphonoformate Crystalluria, A Warning Signal of Foscarnet-Induced Kidney Injury
por: Deffert, Christine, et al.
Publicado: (2020)

Very severe immune thrombocytopenia following SARS-CoV-2 vaccination requiring splenectomy: a case report
por: Weiner, Marc, et al.
Publicado: (2022)

Transient paraproteinemia after allogeneic hematopoietic stem cell transplantation is an underexplored phenomenon associated with graft versus host disease
por: Widmer, Corinne C., et al.
Publicado: (2017)

Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study
por: Héritier, Jérémie, et al.
Publicado: (2022)

Long–Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T–Cell Lymphoma; Results From a Single Institution Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2020)

T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
por: Noetzli, Jasmine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aka9e675u2fmlsqfe5277pmhpj